News|Webcasts|August 8, 2023

Rethinking Oncology Trial Strategy: New Approaches for an Evolving Landscape

Author(s)IQVIA

Webinar Date/Time: Thursday, September 7th, 2023 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

This webinar will address global oncology trends and how they impact sponsors preparing for early phase oncology trials.

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/global-oncology

Event Overview:

Global oncology R&D continues to expand, bringing exciting new treatment options to patients. Seventy percent of the R&D pipeline is driven by the innovation of biotech companies. This creates immense pressure to deliver novel treatments and secure investor funding in a highly complex environment.

Join this webinar to hear from experts with the IQVIA Institute and IQVIA Biotech about global oncology trends impacting sponsors and how to optimize clinical trial strategy.

Three key take-aways

  • Evaluate findings from the 2023 Global Oncology Trends report significant to biotech sponsors
  • Explore nuances of early phase oncology trial design and strategy
  • Understand considerations for platform design trials to help increase accessibility to new treatment options
  • Review progress made to improve representation of race and ethnicity in clinical trial subjects; learn how to build diversity planning in clinical trial protocols


Speakers:

Murray Aitken
Executive Director
IQVIA Institute for Human Data Science

As head of the IQVIA Institute for Human Data Science, Murray Aitken provides policy setters and decision-makers in the global health sector with evidence, analysis, and insights that contribute to the advancement of Human Data Science to improve human health outcomes.

Murray is tasked with creating and managing a research agenda that leaders in global governments, payers, providers, academia, and the life sciences industry use to accelerate the understanding of global trends in disease patterns, data science, and technology. This research is used to foster innovation critical to evidence-based decision-making and the advancement of human health.

He holds an MBA, with distinction, from Harvard University and a Master of Commerce from the University of Auckland in New Zealand.


Gerhard Du Toit
Global Oncology Head
IQVIA Biotech

As Global Head of Oncology, Gerhard Du Toit oversees all aspects of clinical project management to optimize strategic plans and enhance delivery for early and late phase oncology clinical trials. He is committed to delivering compliant, expeditious, ethical solutions that respect patient safety, meet GCP requirements, and add value to the needs of oncology customers. Working for several global clinical research organizations in his career, Gerhard is a seasoned healthcare executive with more than 25 years of experience in project, clinical and data management, business development and statistics.

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/global-oncology


Related to this article

Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
What It Actually Means to Embed the Patient Voice in Trial Design
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written—and what it looks like when patients and caregivers tell you a trial was designed with them in mind.
© ABCDstock - © ABCDstock - stock.adobe.com
Patient-centricity remains largely consultative in most clinical research, yet rare disease communities demonstrate that genuine partnership from protocol inception improves feasibility, reduces unnecessary burden, and identifies outcomes that matter to patients themselves.
Introducing The Human Side of Clinical Trials
This pilot episode of The Human Side of Clinical Trials introduces a framework from Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., exploring why operational failures in clinical trials often trace back to gaps in human readiness rather than process design alone.
© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.